Editorial Commentary: Clinical Significance of HIV Subtype Variability in Regard to Treatment Outcome

Affiliations

Editorial

Mark A Wainberg. Clin Infect Dis. 2015.

. 2015 May 15;60(10):1550-1.

doi: 10.1093/cid/civ107. Epub 2015 Feb 13.

¹ McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada.

No abstract available

Keywords: HIV subtype; resistance; K65R; V106M; clinical outcome.

Comment on

Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.
Kantor R, Smeaton L, Vardhanabhuti S, Hudelson SE, Wallis CL, Tripathy S, Morgado MG, Saravanan S, Balakrishnan P, Reitsma M, Hart S, Mellors JW, Halvas E, Grinsztejn B, Hosseinipour MC, Kumwenda J, La Rosa A, Lalloo UG, Lama JR, Rassool M, Santos BR, Supparatpinyo K, Hakim J, Flanigan T, Kumarasamy N, Campbell TB, Eshleman SH; AIDS Clinical Trials Group (ACTG) A5175 Study Team. Kantor R, et al. Clin Infect Dis. 2015 May 15;60(10):1541-9. doi: 10.1093/cid/civ102. Epub 2015 Feb 13. Clin Infect Dis. 2015. PMID: 25681380 Free PMC article.